Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19380411.
- Also identified by DOI 10.2967/jnumed.108.057216.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite recognized limitations, structural imaging with CT remains the standard technique for evaluating the response of lung cancer to both chemotherapy and radiotherapy. This evaluation has become increasingly important with the advent of neoadjuvant therapy before surgery. The high uptake of (18)F-FDG in most lung cancers and the demonstration that successful treatment reduces uptake have led to increasing enthusiasm for the use of PET and PET/CT to assess the therapeutic response. In this review, theoretic considerations and current evidence supporting the role of (18)F-FDG PET are discussed.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Fluorodeoxyglucose F18
- Lung Neoplasms
- Positron-Emission Tomography
- Tomography, X-Ray Computed